Global Short-acting B2 Agonists market size is predicted to grow from US$ 4892 million in 2025 to US$ 6281 million in 2031; it is expected to grow at a CAGR of 4.3% from 2025 to 2031. Get Access Now!

Global Short-acting B2 Agonists Market Growth Status and Outlook 2025-2031

The global Short-acting B2 Agonists market size is predicted to grow from US$ 4892 million in 2025 to US$ 6281 million in 2031; it is expected to grow at a CAGR of 4.3% from 2025 to 2031. Short-acting B2 agonists (SABAs) arealbuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm caused by COPD, bronchial asthma, or emphysema. The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products. Infinity Market Research newest research report, the Short-acting B2 Agonists Industry Forecast looks at past sales and reviews total world Short-acting B2 Agonists sales in 2024, providing a comprehensive analysis by region and market sector of projected Short-acting B2 Agonists sales for 2025 through 2031. With Short-acting B2 Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Short-acting B2 Agonists industry. This Insight Report provides a comprehensive analysis of the global Short-acting B2 Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short-acting B2 Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Short-acting B2 Agonists market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short-acting B2 Agonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short-acting B2 Agonists. This report presents a comprehensive overview, market shares, and growth opportunities of Short-acting B2 Agonists market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Albuterol &nbsp;&nbsp;&nbsp; Metaproterenol &nbsp;&nbsp;&nbsp; Levalbuterol &nbsp;&nbsp;&nbsp; Other Segmentation by Application: &nbsp;&nbsp;&nbsp; COPD &nbsp;&nbsp;&nbsp; Asthma &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Bayer AG &nbsp;&nbsp;&nbsp; Teva &nbsp;&nbsp;&nbsp; Roche &nbsp;&nbsp;&nbsp; Viatris &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; Cipla Limited &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Merck Key Questions Addressed in this Report What is the 10-year outlook for the global Short-acting B2 Agonists market? What factors are driving Short-acting B2 Agonists market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Short-acting B2 Agonists market opportunities vary by end market size? How does Short-acting B2 Agonists break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Short-acting B2 Agonists Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Short-acting B2 Agonists by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Short-acting B2 Agonists by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Short-acting B2 Agonists Segment by Type &nbsp;2.2.1 Albuterol &nbsp;2.2.2 Metaproterenol &nbsp;2.2.3 Levalbuterol &nbsp;2.2.4 Other &nbsp;2.3 Short-acting B2 Agonists Sales by Type &nbsp;2.3.1 Global Short-acting B2 Agonists Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Short-acting B2 Agonists Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Short-acting B2 Agonists Sale Price by Type (2020-2025) &nbsp;2.4 Short-acting B2 Agonists Segment by Application &nbsp;2.4.1 COPD &nbsp;2.4.2 Asthma &nbsp;2.4.3 Other &nbsp;2.5 Short-acting B2 Agonists Sales by Application &nbsp;2.5.1 Global Short-acting B2 Agonists Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Short-acting B2 Agonists Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Short-acting B2 Agonists Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Short-acting B2 Agonists Breakdown Data by Company &nbsp;3.1.1 Global Short-acting B2 Agonists Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Short-acting B2 Agonists Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Short-acting B2 Agonists Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Short-acting B2 Agonists Revenue by Company (2020-2025) &nbsp;3.2.2 Global Short-acting B2 Agonists Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Short-acting B2 Agonists Sale Price by Company &nbsp;3.4 Key Manufacturers Short-acting B2 Agonists Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Short-acting B2 Agonists Product Location Distribution &nbsp;3.4.2 Players Short-acting B2 Agonists Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Short-acting B2 Agonists by Geographic Region &nbsp;4.1 World Historic Short-acting B2 Agonists Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Short-acting B2 Agonists Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Short-acting B2 Agonists Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Short-acting B2 Agonists Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Short-acting B2 Agonists Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Short-acting B2 Agonists Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Short-acting B2 Agonists Sales Growth &nbsp;4.4 APAC Short-acting B2 Agonists Sales Growth &nbsp;4.5 Europe Short-acting B2 Agonists Sales Growth &nbsp;4.6 Middle East & Africa Short-acting B2 Agonists Sales Growth 5 Americas &nbsp;5.1 Americas Short-acting B2 Agonists Sales by Country &nbsp;5.1.1 Americas Short-acting B2 Agonists Sales by Country (2020-2025) &nbsp;5.1.2 Americas Short-acting B2 Agonists Revenue by Country (2020-2025) &nbsp;5.2 Americas Short-acting B2 Agonists Sales by Type (2020-2025) &nbsp;5.3 Americas Short-acting B2 Agonists Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Short-acting B2 Agonists Sales by Region &nbsp;6.1.1 APAC Short-acting B2 Agonists Sales by Region (2020-2025) &nbsp;6.1.2 APAC Short-acting B2 Agonists Revenue by Region (2020-2025) &nbsp;6.2 APAC Short-acting B2 Agonists Sales by Type (2020-2025) &nbsp;6.3 APAC Short-acting B2 Agonists Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Short-acting B2 Agonists by Country &nbsp;7.1.1 Europe Short-acting B2 Agonists Sales by Country (2020-2025) &nbsp;7.1.2 Europe Short-acting B2 Agonists Revenue by Country (2020-2025) &nbsp;7.2 Europe Short-acting B2 Agonists Sales by Type (2020-2025) &nbsp;7.3 Europe Short-acting B2 Agonists Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Short-acting B2 Agonists by Country &nbsp;8.1.1 Middle East & Africa Short-acting B2 Agonists Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Short-acting B2 Agonists Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Short-acting B2 Agonists Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Short-acting B2 Agonists Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Short-acting B2 Agonists &nbsp;10.3 Manufacturing Process Analysis of Short-acting B2 Agonists &nbsp;10.4 Industry Chain Structure of Short-acting B2 Agonists 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Short-acting B2 Agonists Distributors &nbsp;11.3 Short-acting B2 Agonists Customer 12 World Forecast Review for Short-acting B2 Agonists by Geographic Region &nbsp;12.1 Global Short-acting B2 Agonists Market Size Forecast by Region &nbsp;12.1.1 Global Short-acting B2 Agonists Forecast by Region (2026-2031) &nbsp;12.1.2 Global Short-acting B2 Agonists Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Short-acting B2 Agonists Forecast by Type (2026-2031) &nbsp;12.7 Global Short-acting B2 Agonists Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Bayer AG &nbsp;13.1.1 Bayer AG Company Information &nbsp;13.1.2 Bayer AG Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.1.3 Bayer AG Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Bayer AG Main Business Overview &nbsp;13.1.5 Bayer AG Latest Developments &nbsp;13.2 Teva &nbsp;13.2.1 Teva Company Information &nbsp;13.2.2 Teva Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.2.3 Teva Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Teva Main Business Overview &nbsp;13.2.5 Teva Latest Developments &nbsp;13.3 Roche &nbsp;13.3.1 Roche Company Information &nbsp;13.3.2 Roche Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.3.3 Roche Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Roche Main Business Overview &nbsp;13.3.5 Roche Latest Developments &nbsp;13.4 Viatris &nbsp;13.4.1 Viatris Company Information &nbsp;13.4.2 Viatris Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.4.3 Viatris Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Viatris Main Business Overview &nbsp;13.4.5 Viatris Latest Developments &nbsp;13.5 GSK &nbsp;13.5.1 GSK Company Information &nbsp;13.5.2 GSK Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.5.3 GSK Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 GSK Main Business Overview &nbsp;13.5.5 GSK Latest Developments &nbsp;13.6 Cipla Limited &nbsp;13.6.1 Cipla Limited Company Information &nbsp;13.6.2 Cipla Limited Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.6.3 Cipla Limited Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Cipla Limited Main Business Overview &nbsp;13.6.5 Cipla Limited Latest Developments &nbsp;13.7 Johnson & Johnson &nbsp;13.7.1 Johnson & Johnson Company Information &nbsp;13.7.2 Johnson & Johnson Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.7.3 Johnson & Johnson Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Johnson & Johnson Main Business Overview &nbsp;13.7.5 Johnson & Johnson Latest Developments &nbsp;13.8 Merck &nbsp;13.8.1 Merck Company Information &nbsp;13.8.2 Merck Short-acting B2 Agonists Product Portfolios and Specifications &nbsp;13.8.3 Merck Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Merck Main Business Overview &nbsp;13.8.5 Merck Latest Developments 14 Research Findings and Conclusion

Report	Global Short-acting B2 Agonists Market Growth 2025-2031
Selected License	Multi ID: LPI35814

Buyer Information

Order Summary